Keywords: abbott, labs, files, nda, abt-378/r, its, new

Abbott Labs files NDA for ABT-378/r, its new protease inhibitor

Article | 02 June 2000

Print This

Abbott Laboratories says that it has filed for US approval to market itsnew antiretroviral agent, ABT-378/r (lopinivir plus ritonavir), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in